PF4

Platelet Factor 4 (PF4), also known as CXCL4, is an exercise-induced chemokine released during platelet degranulation that crosses the blood–brain barrier to promote hippocampal neurogenesis and synaptic plasticity through the activation of CXCR3 receptors PMID 41076272PMID 40818821PMID 39818278. By mitigating neuroinflammation and potentially upregulating the longevity factor Klotho, PF4 effectively reverses age-related cognitive deficits and supports brain rejuvenation, positioning it as a promising therapeutic target for Alzheimer's disease PMID 40818821PMID 39818278PMID 39335489.

• CNS Signaling (CXCR3 Receptor): PF4 is capable of crossing the blood–brain barrier (BBB). Once in the brain, it acts primarily through the CXCR3 receptor on hippocampal neurons. This signaling pathway is critical for PF4-induced improvements in synaptic regulation and cognition PMID 40818821.
• Neurogenesis: PF4 promotes the proliferation of neural progenitor cells in the dentate gyrus of the hippocampus. It activates genes associated with neuronal differentiation and development PMID 40818821PMID 39818278.
• Klotho Upregulation: In the context of neuroprotection, PF4 has been observed to upregulate Klotho, a longevity-associated protein known for its cognitive benefits PMID 40818821.
• Immune Modulation: It modulates the recruitment and activation of immune cells, helping to attenuate neuroinflammation in specific pathological models PMID 40818821.

PF4 is classified as an exerkine because its release into the systemic circulation is robustly stimulated by physical activity, specifically through the activation of platelets.

• Exercise-Induced Degranulation: Acute exercise triggers platelet activation and degranulation, leading to a significant rise in plasma levels of soluble mediators including PF4 PMID 41076272PMID 40818821.
• Systemic to Central Communication: It acts as a signaling messenger that transfers the systemic benefits of exercise (from blood platelets) to the brain, specifically ameliorating age-related regenerative deficits in mouse models PMID 39818278PMID 39335489.

• Cognitive Rescue & Aging: PF4 has been shown to restore cognitive function and rejuvenate hippocampal neurogenesis in aged mice, effectively reversing age-related regenerative deficits PMID 39818278PMID 39335489.
• Alzheimer’s Disease (AD): In AD models, PF4 alleviates neuroinflammation and offers neuroprotection, potentially via the upregulation of Klotho. Cross-sectional studies have indicated that decreased serum PF4 levels correlate with cognitive decline in AD patients, suggesting its potential utility as a biomarker if not a therapeutic PMID 40818821.
• Neuroplasticity: By enhancing synaptic plasticity and reducing neuroinflammation, PF4 contributes to overall brain health and resilience against neurodegeneration PMID 40818821PMID 39818278.

1. Neuroprotection and Cognitive Rejuvenation

• A significant body of recent evidence positions PF4 as a rejuvenative factor capable of reversing age-related cognitive decline PMID 40749766PMID 39364349. Systemic administration of PF4 has been shown to mitigate neuroinflammation, enhance synaptic plasticity, and improve cognition in aged mice, mediated partially through the CXCR3 receptor PMID 40193115. Specifically, PF4 supplementation attenuated cognitive impairments in models of age-related perioperative neurocognitive disorders (PND) by regulating the complement C3/C3aR pathway PMID 40659841. Clinical data further supports this, showing that decreased serum PF4 levels correlate with cognitive decline and core biomarkers in Alzheimer's disease patients PMID 39855320. Beyond the brain, PF4 demonstrates neuroprotective properties in the retina by attenuating microglial inflammation in glaucoma models PMID 40118133 and accelerates peripheral nerve regeneration by regulating Schwann cells PMID 37488866.

2. Sepsis, Inflammation, and Cancer

• Human PF4 infusion was found to limit thrombosis and endothelial injury by stabilizing cell-free DNA and neutrophil extracellular traps (NETs) PMID 37991024. In respiratory health, the PF4 variant CXCL4L1 effectively mitigated papain-induced asthma via TLR4 signaling in murine models PMID 41438487. Furthermore, secretory PF4 has been identified as a mechanism for hindering melanoma metastasis by inhibiting the MAPK/ERK signaling pathway PMID 34421345.

3. PF4 as a Target for Inhibition

• Conversely, "anti-PF4" strategies are required for conditions where the chemokine drives pathology. Research indicates that neutralizing PF4 is a potential therapeutic strategy for fibrosis-driven diseases, including systemic sclerosis PMID 40141068PMID 34986347 and myelofibrosis, where PF4 promotes myofibroblast differentiation PMID 39025985. Similarly, inhibiting PF4 or its upstream regulators (like SPI1) may offer therapeutic benefits in multiple sclerosis by reducing NET formation PMID 40632337 and in antiphospholipid syndrome (APS), where PF4 contributes to immunothrombosis PMID 41279156.